ALEC – Alector Inc.
ALEC — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
8.07
Margin Of Safety %
Put/Call OI Ratio
0.01
EPS Next Q Diff
0.06
EPS Last/This Y
0.26
EPS This/Next Y
0.14
Price
2.01
Target Price
2.88
Analyst Recom
2.88
Performance Q
37.93
Upside
-1,003.5%
Beta
0.59
Ticker: ALEC
20 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | ALEC | 2.45 | 0.01 | 0.01 | 6236 |
| 2026-03-02 | ALEC | 2.2 | 0.01 | 0.00 | 6055 |
| 2026-03-03 | ALEC | 2.11 | 0.01 | 0.00 | 6015 |
| 2026-03-04 | ALEC | 2.15 | 0.01 | 0.26 | 6017 |
| 2026-03-05 | ALEC | 2 | 0.01 | 0.04 | 6013 |
| 2026-03-06 | ALEC | 2.01 | 0.01 | 0.01 | 6011 |
| 2026-03-09 | ALEC | 2.18 | 0.01 | 0.08 | 5983 |
| 2026-03-10 | ALEC | 2.37 | 0.01 | 0.00 | 5992 |
| 2026-03-11 | ALEC | 2.33 | 0.01 | 0.00 | 6046 |
| 2026-03-12 | ALEC | 2.23 | 0.01 | 0.00 | 6020 |
| 2026-03-13 | ALEC | 2.23 | 0.01 | 0.00 | 6020 |
| 2026-03-17 | ALEC | 2.24 | 0.01 | 0.03 | 5944 |
| 2026-03-18 | ALEC | 2.06 | 0.01 | 2.00 | 5913 |
| 2026-03-19 | ALEC | 2.06 | 0.01 | 1.50 | 5913 |
| 2026-03-20 | ALEC | 2.05 | 0.01 | 0.05 | 5913 |
| 2026-03-23 | ALEC | 2.05 | 0.01 | 0.02 | 4830 |
| 2026-03-24 | ALEC | 2.09 | 0.01 | 0.04 | 4828 |
| 2026-03-25 | ALEC | 2.17 | 0.01 | 0.00 | 4852 |
| 2026-03-26 | ALEC | 2.12 | 0.01 | 0.00 | 4869 |
| 2026-03-27 | ALEC | 2.01 | 0.01 | 5.00 | 4850 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | ALEC | 2.46 | -1716.6 | - | -1.43 |
| 2026-03-02 | ALEC | 2.20 | 31.7 | - | -0.99 |
| 2026-03-03 | ALEC | 2.11 | 31.7 | - | -0.99 |
| 2026-03-04 | ALEC | 2.15 | 31.7 | - | -0.99 |
| 2026-03-05 | ALEC | 2.00 | 31.7 | - | -0.99 |
| 2026-03-06 | ALEC | 2.01 | 31.7 | - | -0.99 |
| 2026-03-09 | ALEC | 2.19 | 25.2 | - | -1.13 |
| 2026-03-10 | ALEC | 2.37 | 25.2 | - | -1.13 |
| 2026-03-11 | ALEC | 2.33 | 25.2 | - | -1.13 |
| 2026-03-12 | ALEC | 2.24 | 25.2 | - | -1.13 |
| 2026-03-13 | ALEC | 2.21 | 25.2 | - | -1.13 |
| 2026-03-17 | ALEC | 2.24 | 25.2 | - | -1.13 |
| 2026-03-18 | ALEC | 2.06 | 25.2 | - | -1.13 |
| 2026-03-19 | ALEC | 2.06 | 25.2 | - | -1.13 |
| 2026-03-20 | ALEC | 2.05 | 25.2 | - | -1.13 |
| 2026-03-23 | ALEC | 2.05 | 25.2 | - | -1.13 |
| 2026-03-24 | ALEC | 2.09 | 25.2 | - | -1.13 |
| 2026-03-25 | ALEC | 2.17 | 25.2 | - | -1.13 |
| 2026-03-26 | ALEC | 2.12 | 25.2 | - | -1.13 |
| 2026-03-27 | ALEC | 2.01 | 25.2 | - | -1.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | ALEC | -0.87 | -0.60 | 8.28 |
| 2026-03-02 | ALEC | -0.82 | 0.33 | 8.19 |
| 2026-03-03 | ALEC | -1.15 | 0.33 | 8.19 |
| 2026-03-04 | ALEC | -1.16 | 0.33 | 8.19 |
| 2026-03-05 | ALEC | -0.89 | 0.33 | 8.19 |
| 2026-03-06 | ALEC | -0.89 | 0.33 | 8.19 |
| 2026-03-09 | ALEC | -0.89 | 0.32 | 8.19 |
| 2026-03-10 | ALEC | -0.89 | 0.32 | 8.19 |
| 2026-03-11 | ALEC | -0.89 | 0.32 | 8.06 |
| 2026-03-12 | ALEC | -0.89 | 0.32 | 8.06 |
| 2026-03-13 | ALEC | -0.89 | 0.32 | 8.06 |
| 2026-03-17 | ALEC | -0.89 | 0.36 | 8.06 |
| 2026-03-18 | ALEC | -0.89 | 0.36 | 8.06 |
| 2026-03-19 | ALEC | -0.89 | 0.36 | 8.06 |
| 2026-03-20 | ALEC | -0.89 | 0.36 | 8.06 |
| 2026-03-23 | ALEC | -0.89 | 0.36 | 8.06 |
| 2026-03-24 | ALEC | -0.89 | 0.36 | 8.06 |
| 2026-03-25 | ALEC | -0.89 | 0.36 | 8.07 |
| 2026-03-26 | ALEC | -0.89 | 0.36 | 8.07 |
| 2026-03-27 | ALEC | -0.89 | 0.36 | 8.07 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.34
Avg. EPS Est. Current Quarter
-0.31
Avg. EPS Est. Next Quarter
-0.28
Insider Transactions
-0.89
Institutional Transactions
0.36
Beta
0.59
Average Sales Estimate Current Quarter
11
Average Sales Estimate Next Quarter
11
Fair Value
Quality Score
7
Growth Score
24
Sentiment Score
57
Actual DrawDown %
95.4
Max Drawdown 5-Year %
-97.7
Target Price
2.88
P/E
Forward P/E
PEG
P/S
10.49
P/B
7.2
P/Free Cash Flow
EPS
-1.39
Average EPS Est. Cur. Y
-1.13
EPS Next Y. (Est.)
-0.99
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-679.16
Relative Volume
0.51
Return on Equity vs Sector %
-493.7
Return on Equity vs Industry %
-477.4
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.18
EBIT Estimation
◆
ALEC
Healthcare
$2.00
📉
Swing / Pullback
Buy the dip on strong trends
WATCH
Trend
6/20
Pullback
16/25
Volume
11/15
Valuation
12/20
TP/AR
4/10
Options
7/10
RSI
44.4
Range 1M
15.8%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
2/25
Growth
9/30
Estimates
6/20
Inst/Vol
6/15
Options
5/10
EPS Yr
33.5%
EPS NY
4.6%
52W%
45.1%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+44% upside
Quality
5/30
Valuation
12/30
Growth
11/25
Stability
5/10
LT Trend
1/5
Upside
+44%
Quality
7
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 103
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC
Latest News
—
Caricamento notizie per ALEC…
stock quote shares ALEC – Alector Inc. Stock Price stock today
news today ALEC – Alector Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALEC – Alector Inc. yahoo finance google finance
stock history ALEC – Alector Inc. invest stock market
stock prices ALEC premarket after hours
ticker ALEC fair value insiders trading